The Daily Biologics

Peptide therapeutics are a $140B market, but the peptides everyone's talking about online — BPC-157, TB-500, melanotan II — aren't FDA-approved for humans. Now HHS Secretary RFK Jr. is personally reversing a 2023 FDA safety determination, over the objections of the officials who wrote it.

Samsung Biologics' all-cash acquisition of PolyPeptide Group — the largest South Korean biopharma deal ever — signals that peptide manufacturing capacity, not discovery, is the binding constraint on the GLP-1 era. Same week, Bachem dropped $615M on a new Swiss facility. The picks-and-shovels play in peptides is accelerating.

For decades, small molecules dominated drug development — elegant chemistry that blocked receptors, inhibited enzymes, and suppressed symptoms. Now a $140 billion peptide therapeutics market is rewriting the playbook. Peptides sit in the Goldilocks zone between small molecules and biologics: specific enough to engage complex protein-protein interactions, small enough to penetrate tissues and cross barriers, and versatile enough to be conjugated to radionuclides, toxins, and drug payloads. The shift from masking disease to solving it at the pathway level may be the most important structural change in pharmaceutical R&D since the introduction of monoclonal antibodies.

On July 1, CMS launched the Medicare GLP-1 Bridge — a time-limited demonstration program covering obesity drugs for the first time in Medicare's history. Several million seniors are eligible. Novo Nordisk and Eli Lilly secured a $245 net price. The fiscal and market implications are enormous — and the clock is ticking.

Up to 40% of weight lost on GLP-1 drugs like semaglutide comes from lean muscle mass — a growing clinical concern for older patients and long-term users. Biohaven's taldefgrobep alfa, a myostatin-activin pathway inhibitor with a clean 700-patient safety record, just completed Phase 2 enrollment targeting fat loss with simultaneous muscle preservation. Phase 2 topline data expected 2H 2026 could reframe the obesity drug conversation.

Three drug classes developed for diabetes — GLP-1 receptor agonists, SGLT2 inhibitors, and finerenone — are now formally recommended first-line therapies across the new CKM syndrome guideline. The FLOW trial proved semaglutide protects kidneys and hearts independent of blood sugar control. Here's the clinical evidence, and the commercial market-expansion story behind it.

AI-discovered drugs are passing Phase I at 80-90% versus a 40-52% historical average, and generative antibody design (Chai-2, Isomorphic's IsoDDE) is real technical progress. But as of mid-2026, zero AI-discovered drugs have FDA approval, and Phase II/III — where efficacy actually gets tested — still shows no clear AI advantage. Here's the evidence, company by company.

Samsung Biologics' all-cash acquisition of PolyPeptide Group — the largest South Korean biopharma deal ever — signals that peptide manufacturing capacity, not discovery, is the binding constraint on the GLP-1 era. Same week, Bachem dropped $615M on a new Swiss facility. The picks-and-shovels play in peptides is accelerating.

On July 1, CMS launched the Medicare GLP-1 Bridge — a time-limited demonstration program covering obesity drugs for the first time in Medicare's history. Several million seniors are eligible. Novo Nordisk and Eli Lilly secured a $245 net price. The fiscal and market implications are enormous — and the clock is ticking.

Biotech VC hit a multi-year high in H1 2026, but the money is going to the same handful of late-stage mega-caps. Early-stage startups are being starved out, and the structural forces driving the gap aren't temporary.

The FDA approved Tregzi on June 30, 2026 — the first precision-engineered regulatory T cell therapy ever authorized. In a randomized Phase 3 trial in blood cancer patients undergoing allogeneic stem cell transplant, Tregzi achieved 78% one-year cGVHD-free survival versus 38% with standard of care, with 94% overall survival versus 83%. The data doesn't just improve on the existing standard — it reframes what the standard should be.